Radioactivity detection in a target fluid in a fluid communication passageway with a region of scintillator material and a solid-state light-sensor element
10877164 ยท 2020-12-29
Assignee
Inventors
- Stephen James Archibald (Hull, GB)
- David Jenkins (Heslington, GB)
- Nuray Yavuzkanat (Heslington, GB)
- Mohammad Mehdi Nasr Esfahani (Hull, GB)
- Mark Tarn (Hull, GB)
- Nicole Pamme (Hull, GB)
Cpc classification
G01T1/2006
PHYSICS
G01T1/20185
PHYSICS
International classification
Abstract
The present invention relates to a method and apparatus for detecting radioactivity. In particular, but not exclusively, the present invention relates to the detection of radioactivity in a target fluid in a fluid communication passageway using a region of scintillator material (130) to provide light responsive to the presence of radioactive material and at least one silicon photomultiplier (SiPM) (150) for providing an output signal responsive to the light provided by the scintillator material.
Claims
1. An apparatus for detecting radioactivity in a target fluid, comprising: at least one fluid communication passageway for a target fluid: at least one region of scintillator material for providing light responsive to radioactivity in the target fluid; and at least one solid state light sensor element for providing an output signal responsive to the light; wherein the at least one fluid communication passageway comprises a microchannel in a surface of the at least one region of scintillator material.
2. The apparatus of claim 1, wherein the microchannel comprises two face-to-face sub-microchannels provided in opposed surfaces of juxtaposed regions of the at least one region of scintillator material.
3. The apparatus of claim 1, wherein the at least one fluid communication passageway comprises a lumen comprising at least one tube member at a first surface of the at least one region of scintillator material.
4. The apparatus of claim 1, wherein the at least one region of scintillator material comprises at least one layer of plastic scintillator material.
5. The apparatus of claim 4, wherein each of the at least one layer of plastic scintillator material has a thickness selected from 0.05 to 2.05 mm.
6. The apparatus of claim 1, wherein the at least one solid state light sensor element comprises a silicon photomultiplier (SiPM) element.
7. The apparatus of claim 6, wherein said SiPM element comprises an array of SiPM sensors.
8. The apparatus of claim 1, wherein: (i) the microchannel has a width of 100 m to 200 m and a depth of 10 m to 100 m; (ii) the radioactivity comprises positrons; and/or (iii) the at least one region of scintillator material comprises a polymer material doped with scintillating material, a polymer material that exhibits scintillating properties, or both.
9. The apparatus of claim 1 wherein: the at least one fluid communication passageway comprises an inlet and an outlet and follows a linear pathway or a serpentine pathway.
Description
(1) Certain embodiments of the present invention will now be described hereinafter, by way of example only, with reference to the accompanying drawings in which:
(2)
(3)
(4)
(5)
(6)
(7)
(8)
(9)
(10)
(11)
(12)
(13)
(14) In the drawings like reference numerals refer to like parts.
(15)
(16) It will likewise be appreciated that whilst only one microchannel 120 is illustrated in the upper substrate 110 in
(17) As an alternative to milling, hot embossing may be utilised or according to certain embodiments of the present invention the upper substrate 110 can be prepared using photolithography and wet etching procedures. Aptly, glass wafers featuring a chromium layer and a photo resist layer are exposed to UV light through a photo mask featuring a channel design. The region of photo resist exposed to light becomes soluble in photo developer solution, which is then used to strip away the exposed region, revealing the channel design on the chromium layer. The exposed chromium is then etched away, leaving the channel design visible on the glass. A solution of 1% hydrofluoric acid can then be used to etch the channel design into the glass, after which access holes can be drilled into the glass if required to provide inlet or outlet regions. It will be appreciated that other concentrations can be utilised according to a speed of etch desired. Remaining photo resistant chromium layers are then removed and the plate thoroughly cleaned.
(18) As noted above the substrate may alternatively be formed from a variety of different types of material. If silicon is used the silicon could be isotropically etched with hydrofluoric acid (as per glass noted above). Alternatively the silicon can also be anisotropically etched via a solution of potassium hydroxide. Reactive ion etching (RIE) or deep reactive ion etching (DRIE) could also be used.
(19) Channels in polymer material may alternatively be milled via CNC milling, injection moulded, laser cut or polymerised in a mould.
(20) Channels in PDMS may alternatively be prepared using rapid prototyping techniques in which a mould is prepared via photolithography (optionally using an SU-8 photoresist or the like), or by CNC milling or by injection moulding. PDMS elastomer and curing agent are then mixed together, degassed and then poured over the mould and allowed to cure before being peeled off the mould.
(21) Metal substrates may optionally be fabricated via CNC milling or electrical discharge machining (EDM).
(22)
(23) As illustrated in
(24) An example of a possible SiPM that can be used as part of the solid state light sensor layer is a SensL J series SiPM (see www.sensL.com) where a light sensor area is 1 mm1 mm. Optionally sensors having a sensor area of 3 mm3 mm or 6 mm6 mm may be utilised or sensors may be tiled.
(25)
(26) The upper substrate 210 may be secured to the layer 130 of scintillator material and/or PMMA layer 140 via a wide variety of techniques such as use of bonding, double sided tape, hot embossing, ultra sonic welding or the like.
(27) In certain embodiments of the present invention there is provided methods, microfluidic chips and systems for determining at least one characteristic of a sample comprising a compound for in vivo use. According to certain embodiments, a test sample (that is to say a sample to be tested) is formulated for in vivo use prior to testing on the chip and system of embodiments of the present invention. Aptly, the sample is an isotonic saline solution. In an alternative embodiment, the sample is formulated subsequent to testing on the chip and collection from the chip. As used herein, the term sample refers to a material to be investigated or analysed on a microfluidic chip. The sample may comprise a single component or a mixture of components. The sample comprises the compound for in vivo use and optionally other substances. Aptly, the sample may for administration to a patient without further formulation following its analysis using certain embodiments of the present invention.
(28) As used herein, the term compound for in vivo use refers to any compound which is for administration to a patient in need thereof. The patient may be human or animal. The compound may be a pharmaceutical for prophylactic and/or therapeutic use.
(29) In one embodiment, the compound for in vivo use is a radiopharmaceutical. In one embodiment the compound is a radiotracer. A radiotracer is a radiopharmaceutical having a largely unaltered metabolic pathway compared to the unlabelled analogue. It is therefore possible to follow and quantify processes on a particular metabolic pathway by detecting the radioactive decay of the labelling radioisotope.
(30) It will be appreciated that the terms radiotracer, radiopharmaceutical, PET tracer and SPECT tracer as used herein are interchangeable and are exemplary and non-limiting. The mention of one term does not exclude substitution of the other terms in the described embodiment.
(31) Aptly, the radiopharmeutical comprises a radioisotope selected from .sup.89Zr, .sup.64Cu .sup.18F, .sup.99mTc, .sup.11C, .sup.68Ga, .sup.15O or .sup.13N.
(32) Radiotracers are used for diagnostic purposes. Examples of radiotracers include, but are not limited to, .sup.18F-FLT ([.sup.18F]fluoro thymidine), .sup.18F-FDDNP (2-(I-{6-[(2-[.sup.18F]fluoroethyl)(methyl)amino]2-naphthyl}ethylidene)malonitrile), .sup.18F-FHBG (9-[4-[.sup.18F]fluoro-3-(hydroxymethyl)butyl]guanine or [.sup.18F]-penciclovir), .sup.18F-FESP ([.sup.18F]-fluoroethylspiperone), .sup.18F-p-M PPF (4-(2-methoxyphenyl)-I-[2-(N-2-pyridinyl)-p-[.sup.18F]fluorobenzamido]ethylpiperazine), .sup.18F-FDG ([.sup.18F]-2-deoxy-2-fluoro-D-glucose), .sup.18F-FMISO (.sup.18F-fluoromisonidazole) and .sup.18F-sodium fluoride.
(33) .sup.18F-FDG is a radiolabelled sugar molecule. When used with PET imaging, images are produced that show the metabolic activity of tissues. In FDG-PET scanning, the high consumption of the sugar by tumour cells, as compared to the lower consumption by normal surrounding tissues, identifies these cells as cancer cells. FDG is also used to study tumour response to treatment.
(34) Sodium fluoride is an imaging agent for PET imaging of new bone formation. It can assess changes both in normal bone as well as bone tumours. As a result, it can be used to measure response to treatment.
(35) .sup.18F-FLT is a radiolabeled imaging agent that is being investigated in PET imaging for its ability to detect growth in a primary tumor. Studies may also measure the ability of FLT with PET to detect tumor response to treatment.
(36) .sup.18F-FMISO is an imaging agent used with PET imaging that can identify hypoxia (low oxygen) in tissues. Tumours with low oxygen have been shown to be resistant to radiation and chemotherapy.
(37) Alternatively, the radiotracer is a radiopharmaceutical which incorporates a radioisotope selected from the group consisting of .sup.11C, .sup.68Ga and .sup.64Cu.
(38) In one embodiment, the radiotracer is for example .sup.68Ga-NOTA-bis (phosphonate), which can be used as a PET radiotracer for bone imaging, .sup.68Ga-DOTATOC which can be used in PET imaging in patients with meningiomas and/or .sup.68Ga-DOTATATE which can be used in PET imaging in malignant phaeochromocytomas.
(39) In certain embodiments, the radiotracer is .sup.68Ga-PSMA (prostate specific membrane antigen). In certain embodiments, the radiotracer can be used in PET imaging of prostate cancer. In certain embodiments, the radiotracer is .sup.68Ga-pentixafor. In certain embodiments, the radiotracer can be used in PET imaging of small cell lung cancer.
(40) A radiopharmaceutical composition comprises a radiotracer e.g. a radiopharmaceutical, or a pharmaceutically acceptable salt thereof, in association with a pharmaceutically acceptable adjuvant, diluent or carrier. In one embodiment, a radiopharmaceutical composition may comprise the radiopharmaceutical and a saline buffer. Aptly, the radiopharmaceutical is a radiotracer as described herein.
(41) The preparation of a radiopharmaceutical may comprise the following steps: i) separation of a radioisotope from a sample; ii) activation of the radioisotope, for example by solvent exchange; iii) synthesis of the radiopharmaceutical, for example a radiotracer; iv) separation of the radiopharmaceutical, for example a radiotracer, from a reaction mixture; v) formulation of radiopharmaceutical into a radiopharmaceutical composition, for example a radiotracer formulated with a saline buffer; vi) analysis of the radiopharmaceutical composition (quality control (QC)).
(42) Certain embodiments of the present invention relate to a microfluidic chip and system comprising such a chip. A fluid flow can be described as microfluidic (i.e. microfluidic fluid flow) if a fluid passes through a channel having at least one dimension of less than 1 mm, in particular a channel having a dimension of less than 1 mm, e.g. less than 500 m, less than 250 m, less than 200 m, or less than 150 m. This creates laminar flow characteristics (generally having a Reynolds number of less than 100) where diffusion is the dominant cross stream chemical interaction. Consequently, microfluidic fluid flow occurs during the manipulation of small volumes, for example from 1 nl to 100 l, within microstructured devices that features dimensions of the order of 10's to 100's micrometers.
(43) A microfluidic flow system comprises a system having at least one channel for fluid flow, the channel having at least one dimension of less than one 1 mm, for example less than 500 m, e.g. 300 m, 200 m, 150 m, 100 m, 50 m, 20 m or less. The microfluidic flow system comprises a microfluidic device but may also comprise other components that are in fluid communication with the microfluidic device.
(44) In one embodiment, the system comprises one or more channels having a width of, for example, between about around 100 m to about 200 m e.g. about 150 m and a depth of for example about around 10 m to 100 m e.g. about 50 m deep.
(45) A microfluidic chip can be identified by the fact that it has one or more channels with at least one dimension less than 1 mm, for example, less than 500 m, e.g. 300 m, 200 m, 150 m, 100 m, 50 m, 20 m or less, in particular a channel having a dimension of less than 1 mm, e.g. for example, between about 100 m to about 200 m e.g. about 150 m and a depth of for example about around 10 m to 100 m e.g. 50 m deep. The microfluidic chip may be part of a microfluidic flow system. The one or more channels may form a whole or part of a fluid flow path in the chip.
(46) The microfluidic system of certain embodiments of the invention may be a modular system composed of a plurality of separate components, wherein one or more of the components are in fluid communication in use. The system may alternatively be an integrated system wherein one or more e.g. all of the components are provided on a single platform such as for example a microfluidic device e.g. a device comprising a chip. The device may comprise of be comprised in a microfluidic flow system.
(47) As used herein, the term microfluidic chip refers to a device which can be used for synthetic or analytical purposes for samples having a volume of from about 10 nl and 10 ml. In one embodiment, the microfluidic chip is used to process, synthesize and/or analyze samples having a volume of between about 1 l and 2000 l e.g. about 1000 l or less e.g. 500 l or less. In one embodiment, the microfluidic chip is a microfluidic device and/or comprised within a microfluidic device. In certain embodiments, the microfluidic chip may comprise one or more separable modular components e.g. components comprising an electrochemical cell and the like. Aptly, the modular component may comprise a detection zone as described herein.
(48) The Reynolds number which is used to characterise microfluidic flow (i.e. the flow of a fluid through a microfluidic channel is calculated according to equation 1:
(49)
wherein:
L is the most relevant length scale;
is the viscosity;
is the fluid density; and
V.sub.avg is the average velocity of the flow.
For many microchannels:
L=4A/P wherein:equation 2
A is the cross sectional area of the channel; and
P is the wetted perimeter of the channel.
(50) Due to the small dimensions of the channels in a microfluidic device, R.sub.e is usually less than 100, in particular less than 1.0. Fluid flow with a Reynolds number of this magnitude is completely laminar with very little or no turbulence such that molecular transport is relatively predictable.
(51) As described herein, certain embodiments of the present invention relate to the analysis of compounds which are for in vivo administration. According to certain embodiments of the present invention the compound is a radiopharmaceutical such as for example [.sup.18F]FDG, .sup.68Ga-PMSA, .sup.68Ga-pentixafor or the like.
(52) In one embodiment, the radiotracer being analysed is for example .sup.68Ga-NOTA-bis (phosphonate), .sup.68Ga-DOTATOC, .sup.68Ga-DOTATATE, .sup.68Ga-PSMA or .sup.68Ga-pentixafor.
(53) It will be understood by the person skilled in the art that embodiments of the present invention are not limited to the testing of [.sup.18F]FDG. For example, certain embodiments of the present invention relate to devices, systems and methods which perform quality control (QC) testing of other radiotracers e.g. .sup.68Ga-PSMA or .sup.68Ga-pentixafor and/or other compounds which are for in vivo administration. In certain embodiments of the present invention, the devices, systems and methods are for use to determine at least one characteristic of a pharmaceutical compound. Certain embodiments of the present invention are likewise not limited to the identification of radioactivity in target fluids used for in vivo or indeed medical uses.
(54) In one embodiment, following purification, QC tests are performed on a sample of [.sup.18F]FDG in order to ensure that a desired level of radioactivity is present and that the properties of the dose are suitable for injection. As used herein, the terms [.sup.18F]FDG and FDG are interchangeable and relate to the compound 2-[.sup.18F]fluoro-2-deoxy-D-glucose. A summary of the process for preparing [.sup.18F]FDG is as follows:
(55) [.sup.18F]FDG is usually synthesized by way of nucleophilic substitution (Hamacher et al.) and aptly, the procedure follows the steps of: 1. [.sup.18F]fluoride generation by proton bombardment of .sup.18O-enriched cyclotron via a cyclotron; 2. Pre-concentration of aqueous [.sup.18F]fluoride, e.g. an ion exchange column, or electrode trapping. 3. Release of [.sup.18F]fluoride in acetonitrile containing addition of phase transfer catalyst (typically Kryptofix 2.2.2) and potassium carbonate. 4. Radiolabelling reaction of mannose triflate with [.sup.18F]fluoride via S.sub.N2 nucleophilic substitution, producing the acetylated form of [.sup.18F]FDG (i.e. unhydrolysed [.sup.18F]FDG, also referred to as acetylated-[.sup.18F]FDG (ACY-[.sup.18F]FDG) or 2-[.sup.18F]fluoro-1,3,4,6-tetra-O-acetyl-D-glucose ([.sup.18F]FTAG)). 5. Solvent exchange from acetonitrile to water. 6. Hydrolysis of acetylated-[.sup.18F]FDG to [.sup.18F]FDG, either by acid hydrolysis (HCl) or base hydrolysis (NaOH). 7. Purification of the crude [.sup.18F]FDG mixture, e.g. via solid-phase extraction (SPE) cartridge(s). 8. Formulation of the [.sup.18F]FDG dose as an isotonic saline (sodium chloride) solution.
(56) Prior to administration to a patient, the batch of [.sup.18F]FDG has to undergo a number of quality control (QC) tests to ensure it meets the necessary safety requirements. Aptly, certain embodiments of the present invention provide a microfluidic system which can be used to perform the quality control tests of microfluidic quantities of a compound, e.g. [.sup.18F]FDG. Certain embodiments of the present invention provide a measurement value which can be used to determine the characteristic of the sample. The measurement value can then be compared to a predetermined corresponding criterion value to determine whether the sample is suitable for administration to a patient. The predetermined corresponding criterion value can be identified using known literature such as for example although not limited to the current British Pharmacopoeia, US Pharmacopeia, European Pharmacopoeia, International Pharmacopoeia, and the like. Examples of quality control tests which a sample may need to be subjected to are described in more detail below. One such test may be detection of the level of radioactivity in the sample.
(57) The chip 100 illustrated in
(58)
(59)
(60) In more detail
(61) As illustrated in
(62)
(63)
(64) In more detail
(65)
(66) The lower sublayers are intermediate layers between the microchannel and the scintillator of the scintillator layer. The intermediate layer may alternatively be a thin film or coating layer. This can help promote or prevent adhesion between opposed surfaces.
(67)
(68) For example as shown in more detail in
(69) The scintillator layer 730 illustrated In
(70) The chip illustrated in
(71)
(72) In more detail
(73) The tube 902 is located on an upper surface of a scintillator layer 930 which is located over a PMMA layer 940. The PMMA layer is located over an SiPM layer 950 which includes at least one SiPM element.
(74)
(75) It will be appreciated that according to certain other embodiments of the present invention the tube may optionally be partly embedded in an upper substrate layer or a plastic scintillator layer. According to certain other embodiments of the present invention the tube that provides a fluid communication passageway may be wholly embedded in such a layer by, for example, pre-forming a throughhole through a substrate or scintillator material layer into which a tube may be inserted.
(76)
(77) The micro fluidic chip includes a layered structure. The micro fluidic chip 1100 includes a first microchannel 1110 which is in fluid communication with an inlet port 1120. A sample fluid can be introduced into the micro fluidic chip through the inlet port 1120. The first microchannel 1100 includes multiple valve elements. A first valve element 1122 can control movement of a fluid e.g. the sample into the first microchannel. The chip illustrated in
(78) With reference to
(79) The first detection channel and the second detection channel may be in fluid communication via a portion of the sample channel which is provided in the lower planar structure. Thus. in use, a sample or portion thereof is made to flow along the sample channel down the first detection channel along the sample channel in the lower planar structure and then upwardly along the second detection channel. The sample then exits via the outlet 1130.
(80) Aptly the first microchannel 1110 comprises a plurality of valve elements which can be used to direct flow of the sample and/or reagents and/or solutions from the first microchannel to other areas of the micro fluidic chip. In addition the valve elements can be utilised to isolate portions of the fluid in the first microchannel from other areas of the first microchannel. Aptly the valve elements are provided in series. The number of valve elements depends upon how many tests are to be provided on the chip and thus how many detection zone portions of the sample are to be directed to.
(81) The first microchannel 1110 includes an approximately 90 change in direction at a corner 1132 to a second valve element 1134. A first intersecting channel 1136 is provided on the chip. The first intersecting channel 1136 is in fluid communication with a further inlet, referred to herein as a second inlet port 1140. The first intersecting channel intersects the first microchannel at a junction between the second valve element 1134 and a third valve element 1142.
(82) As described herein below each intersecting channel may be provided with a pair of valve elements which prevent flow of fluid from the detection zones during filling of the first microchannel with the sample and/or otherwise control a flow path. Aptly, one of the pair of valve elements is provided in the intersecting channel upstream of the junction between the intersecting channel and the microchannel and one of the pair is provided downstream of the junction. Once a flow of the sample or a portion thereof is desired to be provided to a detection zone as desired the valves of the intersecting channel can be opened to provide a fluid flow path to the detection zone. Aptly each valve is an open/close type valve having only two states or modes of operation.
(83)
(84)
(85) The embodiment illustrated in
(86) In addition, the sample of the compound e.g. a fluorine containing compound such as [.sup.18F]FDG should be tested for the presence and amount of chemical impurities. In terms of chemical purity testing, CIDG refers to 2-chloro-2-deoxy-D-glucose, an impurity that can be present particularly when using acid hydrolysis in which a chloride atom takes the place of the [.sup.18F]fluoride label. A further source of chloride may be an anion exchange cartridge used to pre-concentrate the [.sup.18F]fluoride label in many systems, depending on the counter ion present on the cartridge resin.
(87) Aptly, ACY-[.sup.18F]FDG or alternatively ACY-FDG refers to the acetylated/unhydrolysed form of [.sup.18F]FDG, which is 2-[.sup.18F]fluoro-1,3,4,6-tetra-O-acetyl-D-glucose (also referred to as [.sup.18F]TAG), while partially hydrolysed ACY-[.sup.18F]FDG can also be present.
(88) [.sup.18F]FDM is 2-[.sup.18F]fluoro-2-deoxy-D-mannose, a byproduct that can be produced during the [.sup.18F]FDG synthesis process, and which can also be present in fully or partially hydrolysed form (ACY-[.sup.18F]FDM).
(89) pH
(90) According to the BP, the pH of a dose of a compound for in vivo use, e.g. a [.sup.18F]FDG dose should be in the range of 4.5 to 8.5, although this range can vary in other pharmacopoeias (e.g. pH 4.5 to 7.5 in the USP).
(91) Kryptofix 2.2.2
(92) The aminopolyether, Kryptofix 2.2.2 (4,7,13,16,21,24-hexaoxa-1,10-diazabicyclo[8.8.8] hexacosane), also known as cryptand 2.2.2, is a phase transfer catalyst used during [.sup.18F]FDG synthesis. It incorporates a potassium ion into its cage-like structure, preventing the formation of potassium [.sup.18F]fluoride in acetonitrile and thus leaving the [.sup.18F]fluoride ion to react with the mannose triflate molecule by nucleophilic substitution. However, while an important aspect of the synthesis, Kryptofix 2.2.2, hereafter referred to as K222, is also very toxic, causing apnoea, ptosis and convulsions in patients, while the intravenous LD.sub.50 in rats is 35 mg/kg. Thus, its removal from [.sup.18F]FDG is important and its concentration in a dose must be determined.
(93) The limit of K222 that can be present in [.sup.18F]FDG depends varies between pharmacopoeias, with the EP and BP stating a limit of 2.2 mg per volume of dose (e.g. the maximum amount of K222 that could be in a 10 mL dose would be 2.2 mg, which would be equivalent to 220 g mL.sup.1), while in the USP the limit is set at 50 g mL.sup.1. K222 is essential for many radiolabelling processes involving [.sup.18F]fluoride, and so is not limited to only [.sup.18F]FDG.
(94) While Kryptofix 2.2.2, referred to as aminopolyether in the BP, is usually the phase transfer catalyst of choice in the synthesis of [.sup.18F]FDG by nucleophilic substitution, other catalysts such as tetrabutylammonium and 4-(4-methylpiperidin-1-yl)pyridine can also be employed instead, hence their inclusion in the BP. However, it is worth noting that the BP states that specific tests do not need to be performed if there is no source of the potential impurity (e.g. the test for tetrabutylammonium is not required if Kryptofix 2.2.2 is used as the phase transfer catalyst).
(95) Bacterial Endotoxin
(96) In the case of [.sup.18F]FDG and other radiopharmaceuticals, the presence and/or quantity of bacterial endotoxin must be determined prior to the radiopharmaceutical being deemed safe for administration to a patient. Bacterial endotoxins can be introduced into the radiopharmaceutical manufacturing process by way of for example non sterile tubing, containers, chemicals and/or water.
(97) The tests (for FDG for example) that the plastic scintillator/SiPM would be suitable for include: 1. Determination of the level of radioactivity (which may be performed on the final, useable dose); 2. Determination of half-life: this is to ensure that the radioactivity is due to the desired radionuclide (e.g. the half-life of fluorine-18 is 109.7 min and so when measuring the half-life of FDG the value should be between 105 min and 115 min); 3. If possible, the determination of the energy spectra to ensure that the detected activity is due to the 511 keV gamma photons (or a combined total of 1.022 MeV); 4. For detection of the relative amounts of [.sup.18F]FDG, 2-[.sup.18F]fluoro-2-doexy-D-mannose ([.sup.18F]FDM) following their separation by strong anion exchange chromatography; 5. For detection of the relative amounts of [.sup.18F]fluoride, ACY-[.sup.18F]FDG, and [.sup.18F]FDG following their separation via normal phase or reversed phase chromatography; 6. Radiochemical identity of [.sup.18F]FDG against a standard FDG solution based on its retention time on a strong anion exchange chromatography column.
(98) Each of the above mentioned characteristics and tests can be determined using chips incorporating certain embodiments of the present invention. Once the characteristics of the sample have been determined, a decision can be made as to whether or not the compound is suitable for in vivo use. In certain embodiments of the present invention, the sample has a volume which is only a small percentage greater than a single unit dose of the compound. Thus, a single unit dose of the sample comprising the compound exits the chip and is suitable for administration to a patient, providing all of the sample's characteristics meet the stated requirements for in vivo use.
(99) Certain embodiments of the present invention have been described in which milled channels can be formed in a plastic scintillator layer via CNC milling. The milled piece is then bonded to either a conventional plastic top plate (e.g. PMMA) or to a second piece of plastic scintillator via double sided tape or other bonding technique. Aptly as an alternative injection moulding can be utilised or plastic scintillator having a desired inset region can be provided by direct polymerisation of the plastic scintillator in a mould. As a still further alternative hot embossing can alternatively be utilised to provide a required microchannel design in a sheet of plastic scintillator. It will be appreciated that according to certain embodiments of the present invention hot embossing can be utilised for bonding adjacent layers. Other methods of bonding could include the use of various types of glues, ultrasonic welding, solvent-based bonding or the like.
(100) Certain embodiments of the present invention provide a method and apparatus suitable for quality control (QC). Miniaturised HPLC separations of radiotracer impurities in a microfluidic device can be performed with detection via a microfluidic chip. Certain embodiments of the present invention can also be applied to radio-TLC detection. Aptly in such a case an array of SiPMs is used to cover a large area. Such a technique may optionally also be employed to measure radioactivity levels and for determination of half-life for radionuclidic identity and purity.
(101) Certain other embodiments of the present invention can be utilised for non-QC applications. For example certain embodiments of the present invention can be used to monitor chemical synthesis and/or detection of radiotracers in blood that is being continuously drawn from a patient following injection of the radiotracer and during a PET scan.
(102) Certain embodiments of the present invention have been described in which the plastic scintillator itself features the microfluidic channel. It will be appreciated that the channel might also be moulded in the plastic scintillator via injection moulding or by polymerisation of the plastic within a mould. The channel designs may optionally be hot embossed or laser cut into the plastic scintillator.
(103) It will likewise be appreciated that certain embodiments of the present invention can be utilised more broadly wherever a target fluid may contain radioactive matter. This can occur when a desired radioactive material is introduced but may likewise, as an alternative, be utilised when a target fluid should be free of radioactivity and as such can be utilised as a threat indicator. For example such use can be made of a detector in an environment where a radioactive leak may occur. The radiation detection would thus be a sign of an undesired breach of security measures/shielding.
(104) Throughout the description and claims of this specification, the words comprise and contain and variations of them mean including but not limited to and they are not intended to (and do not) exclude other moieties, additives, components, integers or steps. Throughout the description and claims of this specification, the singular encompasses the plural unless the context otherwise requires. In particular, where the indefinite article is used, the specification is to be understood as contemplating plurality as well as singularity, unless the context requires otherwise.
(105) Features, integers, characteristics or groups described in conjunction with a particular aspect, embodiment or example of the invention are to be understood to be applicable to any other aspect, embodiment or example described herein unless incompatible therewith. All of the features disclosed in this specification (including any accompanying claims, abstract and drawings), and/or all of the steps of any method or process so disclosed, may be combined in any combination, except combinations where at least some of the features and/or steps are mutually exclusive. The invention is not restricted to any details of any foregoing embodiments. The invention extends to any novel one, or novel combination, of the features disclosed in this specification (including any accompanying claims, abstract and drawings), or to any novel one, or any novel combination, of the steps of any method or process so disclosed.
(106) The reader's attention is directed to all papers and documents which are filed concurrently with or previous to this specification in connection with this application and which are open to public inspection with this specification, and the contents of all such papers and documents are incorporated herein by reference.